Hospital Management Asia 2025: Shaping the Future of Asian Healthcare
From Healthcare System Reform to Medical Tourism
Under the theme "Quality, Experience & Leadership in Healthcare: Integrate – Inspire – Innovate," HMA 2025 aims to reaffirm core values in modern hospital governance: driving excellence in quality, enhancing patient experience, and fostering strong leadership.
The conference officially opens on September 10, 2025, with remarks by Prof. Dr. Tran Van Thuan – Vice Minister of Health, Vietnam, alongside HMA organizing committee representatives.
Over the two-day conference, delegates can expect to hear from world-leading experts, including:
Dr Lisa Ishii, Senior Vice President (Operations), Johns Hopkins Health System, USA, who will speak on how hospital leadership can be shaped by lessons from the past and innovations in the future.
Sasa Mutic – President of Radiation Oncology Solutions, who will be presenting ideas and innovations into accelerating cancer survivorship journeys.
There will also be more than 20 in-depth discussion sessions focusing on the three main pillars of:
1. Quality and Safety: infection prevention, AI in diagnosis & treatment, EHR, clinical decision-making;
2. Patient and Staff Experience: healthcare service design, PREMs/PROMs, staff well-being; and
3. Leadership and Organizational Models: Hospital-at-Home, DRG vs FFS business models, ESG, succession strategies, Value-Based Care.
Some prominent topics at the conference include medical tourism, a sector where Thailand has established itself as a global leader and economic powerhouse. Leading institutions such as Bumrungrad International Hospital have established Thailand's reputation for excellence, with Artirat Charukitpipat, CEO, Bumrungrad International Hospital, presenting a case study on how the hospital maintains rigorous international accreditation standards while delivering comprehensive medical services.
Hospitals also grapple with the ongoing challenges of resource optimization and staff wellbeing while maintaining exceptional patient outcomes. Dr Saran Intakul, Deputy Hospital Director, Samitivej Srinakarin Hospital, will be presenting a compelling case study drawing from real-world experience including his team's exemplary response to the 2024 Singapore Airlines SQ321 turbulence incident that led to an influx of patients to the hospital, demonstrating how strategic workflow preparation and connected care systems enable healthcare facilities to efficiently manage mass-casualty events.
Celebrating Innovation and Connecting Practice
A notable highlight at HMA 2025 will be two highly anticipated panel sessions on each day of the conference.
The " DRG Debate" session will see experts from Malaysia and Thailand's health ministries and associations exchanging opinions in a fiery discussion over the dilemma on whether the Diagnosis-Related Group or Fee-For-Service business model is better-suited to deliver both cost containment and quality care in Southeast Asia's diverse healthcare markets.
Meanwhile, the " Vietnam Four" panel session will bring together representatives from four exemplary hospital systems in Vietnam: Hoa Lam Group, FV Hospital, Vinmec International Healthcare System, and Hoan My Medical Corporation. Here, these representatives will share practical experiences and strategies for developing effective hospital models.
HMA 2025 wraps up with its highly-anticipated Gala Dinner and the HMA Awards 2025 ceremony, honoring outstanding innovations in hospital management across Asia. Award-winning organizations are recognized as exemplary models of innovation throughout the region. The organizing committee encourages guests to wear traditional national attire, celebrating Asian cultural diversity and fostering multinational connections.
Following the main event, on September 12, international delegates will participate in a field visit program to leading hospitals in Ho Chi Minh City: FV Hospital, Gia An 115, City International Hospital, and Tam Anh Hospital. This provides an opportunity for international delegates to directly experience the operational models, treatment protocols, and innovative strategies being implemented in Vietnam.
HMA 2025 promises to be a forum for knowledge sharing, professional networking, and creating solutions for the future of Asian healthcare.
For more information, please contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
Hospital Management Asia 2025: Shaping the Future of Asian Healthcare
HO CHI MINH CITY, Vietnam, Aug. 13, 2025 /PRNewswire/ -- Hospital Management Asia (HMA), the region's premier annual event for hospital management and healthcare, is set to officially take place at GEM Center, Ho Chi Minh City. This year's conference, organised by Clarion Events Pte Ltd, will gather over 100 speakers from 15 countries and territories, alongside hundreds of hospital leaders, medical professionals, and healthcare organizations from across the region and beyond. From Healthcare System Reform to Medical Tourism Under the theme "Quality, Experience & Leadership in Healthcare: Integrate – Inspire – Innovate," HMA 2025 aims to reaffirm core values in modern hospital governance: driving excellence in quality, enhancing patient experience, and fostering strong leadership. The conference officially opens on September 10, 2025, with remarks by Prof. Dr. Tran Van Thuan – Vice Minister of Health, Vietnam, alongside HMA organizing committee representatives. Over the two-day conference, delegates can expect to hear from world-leading experts, including: Dr Lisa Ishii, Senior Vice President (Operations), Johns Hopkins Health System, USA, who will speak on how hospital leadership can be shaped by lessons from the past and innovations in the future. Sasa Mutic – President of Radiation Oncology Solutions, who will be presenting ideas and innovations into accelerating cancer survivorship journeys. There will also be more than 20 in-depth discussion sessions focusing on the three main pillars of: 1. Quality and Safety: infection prevention, AI in diagnosis & treatment, EHR, clinical decision-making; 2. Patient and Staff Experience: healthcare service design, PREMs/PROMs, staff well-being; and 3. Leadership and Organizational Models: Hospital-at-Home, DRG vs FFS business models, ESG, succession strategies, Value-Based Care. Some prominent topics at the conference include medical tourism, a sector where Thailand has established itself as a global leader and economic powerhouse. Leading institutions such as Bumrungrad International Hospital have established Thailand's reputation for excellence, with Artirat Charukitpipat, CEO, Bumrungrad International Hospital, presenting a case study on how the hospital maintains rigorous international accreditation standards while delivering comprehensive medical services. Hospitals also grapple with the ongoing challenges of resource optimization and staff wellbeing while maintaining exceptional patient outcomes. Dr Saran Intakul, Deputy Hospital Director, Samitivej Srinakarin Hospital, will be presenting a compelling case study drawing from real-world experience including his team's exemplary response to the 2024 Singapore Airlines SQ321 turbulence incident that led to an influx of patients to the hospital, demonstrating how strategic workflow preparation and connected care systems enable healthcare facilities to efficiently manage mass-casualty events. Celebrating Innovation and Connecting Practice A notable highlight at HMA 2025 will be two highly anticipated panel sessions on each day of the conference. The " DRG Debate" session will see experts from Malaysia and Thailand's health ministries and associations exchanging opinions in a fiery discussion over the dilemma on whether the Diagnosis-Related Group or Fee-For-Service business model is better-suited to deliver both cost containment and quality care in Southeast Asia's diverse healthcare markets. Meanwhile, the " Vietnam Four" panel session will bring together representatives from four exemplary hospital systems in Vietnam: Hoa Lam Group, FV Hospital, Vinmec International Healthcare System, and Hoan My Medical Corporation. Here, these representatives will share practical experiences and strategies for developing effective hospital models. HMA 2025 wraps up with its highly-anticipated Gala Dinner and the HMA Awards 2025 ceremony, honoring outstanding innovations in hospital management across Asia. Award-winning organizations are recognized as exemplary models of innovation throughout the region. The organizing committee encourages guests to wear traditional national attire, celebrating Asian cultural diversity and fostering multinational connections. Following the main event, on September 12, international delegates will participate in a field visit program to leading hospitals in Ho Chi Minh City: FV Hospital, Gia An 115, City International Hospital, and Tam Anh Hospital. This provides an opportunity for international delegates to directly experience the operational models, treatment protocols, and innovative strategies being implemented in Vietnam. HMA 2025 promises to be a forum for knowledge sharing, professional networking, and creating solutions for the future of Asian healthcare. For more information, please contact:
Korea Herald
2 days ago
- Korea Herald
The Westin Surabaya Introduces Wellness Oasis: A Journey of Mindful Discoveries
SURABAYA, Indonesia, Aug. 13, 2025 /PRNewswire/ -- On Saturday, 9 August 2025 The Westin Surabaya proudly unveils its latest guest experience: Wellness Oasis, a mindfulness-based wellness program thoughtfully designed to support mental health, inner balance, and rejuvenation. In response to today's growing healthcare constraints and the universal longing for calm, this initiative embraces the rise of wellness tourism by offering guests space for mindful learning and inner renewal. Through grounding rituals such as mindfulness meditation, nature connection, and creative expression, guests are gently guided in how to practice mindfulness. In line with the Indonesian Government's initiative to position health and wellness tourism as a national travel trend, The Westin Surabaya continues to expand its facilities that support guests' mental well-being and physical fitness. According to a study by the Ministry of Tourism of the Republic of Indonesia, wellness tourism in the country encompasses eight key dimensions: fitness, healthy eating, healthcare, spa & beauty, mind-body balance, spirituality & connection, self-development, and eco-tourism & adventure. Rooted in Westin's pillars of Move Well, Feel Well, and Play Well, this experience nurtures emotional well-being while offering a serene path to presence, clarity, and holistic healing. Guests are invited to embark on a self-guided journey through six thoughtfully designed wellness zones, each crafted to nurture both body and mind: " In today's fast-paced world, true luxury lies in the ability to pause, breathe, and be present," said Denny Ristyanto, Multi-Property General Manager of The Westin Surabaya and Four Points by Sheraton Surabaya, Pakuwon Indah. " The Wellness Oasis reflects our commitment to helping guests not just stay well—but thrive in every aspect of their journey." Whether seeking quiet introspection or joyful discovery, the Wellness Oasis encourages every guest to explore, express, and embrace personal well-being in meaningful and lasting ways. For more information and room reservation visit or call at +62-31-29710000. Follow @westinsurabaya on social media for more updates and upcoming promotion. Westin Hotels & Resorts, hospitality's global leader in wellness for more than a decade, empowers guests to transcend the rigors of travel while on the road through the brand's pillars of well-being: Sleep Well, Eat Well, and Move Well. At more than 240 hotels and resorts in over 40 countries and territories, guests can benefit from distinct wellness experiences including the brand's iconic and award-winning Heavenly® Bed, signature WestinWORKOUT® offerings such as its 24/7 Fitness Studios, WestinWORKOUT Routes, and its versatile Gear Lending program, delicious and nutritious menu offerings on their Eat Well menu, and more. For more information, please visit and stay connected on X, Instagram, TikTok, and Facebook. Westin is proud to participate in Marriott Bonvoy®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including free nights and Elite status recognition. To enroll for free or for more information about the program, visit About Marriott Bonvoy® Marriott Bonvoy, Marriott International's award-winning travel platform, connects travelers to the people, places, and passions they love through an extraordinary collection of hotels and experiences worldwide. The platform features over 30 hotel brands and 10,000 destinations, including the largest collection of luxury offerings, distinctive boutique properties, premium home rentals, and more, providing renowned hospitality across the globe. With unrivaled access to the best in entertainment, culinary, sports, outdoor adventure, arts, culture, and more, Marriott Bonvoy offers transformative travel experiences that leave a lasting impression. Marriott Bonvoy membership is free and unlocks unique benefits including the ability to earn points through travel and everyday activities, like purchases with co-branded credit cards. Members can redeem their points for free stays, experiences and more. Visit for more information and download the Marriott Bonvoy app here. Travelers can connect with Marriott Bonvoy on Instagram, TikTok, YouTube, and Facebook.
Korea Herald
2 days ago
- Korea Herald
Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform
SEOUL, South Korea, Aug. 13, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that their proprietary semaglutide microneedle patch achieved more than 80%relative bioavailability compared to the injectable formulation in a pilot human pharmacokinetic study. This was based on the healthy volunteer study using semaglutide microneedle patch using Daewoong Therapeutics' CLOPAM® (CLO sed P acked A ero-pressured M icroneedle) drug-delivery platform. The study directly compared delivery efficiency with semaglutide subcutaneous injection. In the trial, 70 healthy adults received single dose of either a semaglutide microneedle patch or a subcutaneous injection. Plasma concentrations were measured and then compared with results from semaglutide subcutaneous injection under the same conditions. After adjusting to equivalent dose, the patch showed more than 80%relative bioavailability compared with injection. This result is the highest reported for a microneedle patch with the same active ingredient, far exceeding the approximately 30 percent achieved by existing patches. It also showed around 160 times higher bioavailability than semaglutide oral tablet. Therapeutic plasma levels were maintained for one week, supporting the potential for once-weekly dosing with a single high-load patch. The exposure profile was comparable to that of the injectable counterpart, which strengthens the commercial prospects for a patch-based obesity treatment. Technology as the Decisive Factor in the Obesity Market According to Grand View Research, the global obesity therapeutics market is valued at 15.9 billion US dollars in 2024 and is projected to grow to 60.5 billion US dollars by 2030. Currently, therapeutic and safety advantages in the GLP-1 drug class are limited, and experts expect Experts expect delivery technologies improving both bioavailability and patient convenience will be the factor that determines future market leaders. Microneedle patches are attracting attention because they address two key limitations of current therapies: pain of injections and low drug delivery efficiency of oral formulations. While semaglutide oral tablet is available on the market, it has very low bioavailability and requires complex medication regimen, such as fasting before dosing, limiting water intake, and avoiding co-administration with other drugs for chronic patients potentially lowering adherence. A once-weekly microneedle patch offers a simpler, needle-free option that could be used by a wider range of patients, including those who avoid injections. Daewoong's Microneedle Technology Innovation Leading the Global Market The results were made possible by Daewoong Therapeutics' patented CLOPAM® microneedle platform technology, a dissolving-type microneedle technology designed for precise, skin-based drug delivery. The platform uses pressurized drying and hermetic packaging to improve drug uniformity and stability, allowing accurate dosing with minimal contamination risk. CLOPAM® currently has 52 patent filings worldwide and is positioning to be one of Daewoong's leading technologies. Unlike other injectable products containing semaglutide that require cold-chain storage, Daewoong's patches remain stable at room temperature, which can reduce distribution costs. They also help cut down on medical waste from syringes and needles, aligning with sustainability goals in healthcare. Based on these results, Daewoong Therapeutics is planning to broaden the collaborative initiatives to the global market via technology licensing, co-development, and out-licensing to prepare for commercialization. "The microneedle patch must achieve not only high bioavailability but also a drug load sufficient for therapeutic effect," said Bok-Ki Kang, CEO of Daewoong Therapeutics. "In this study, we incorporated a high dose of semaglutide into a single patch and showed the potential for once-weekly application. This overcomes a key limitation of previous microneedle approaches and provides a strong foundation for global technology transfer and commercialization." "Microneedle formats have long promised better adherence, but high-dose delivery has been a challenge," said Seong-Soo Park, CEO of Daewoong Pharmaceutical. "This work is the first to overcome that barrier. We plan to expand microneedle technology to a wide range of biologics to lead the global platform market." About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company headquartered in South Korea. The company develops, manufactures, and markets innovative medicines and healthcare solutions with the mission to improve quality of life worldwide. Daewoong specializes in treatments for intractable and rare diseases, supported by in-house research and development, open innovation, and advanced manufacturing capabilities. Recent achievements include the development and approval of novel drugs for gastroesophageal reflux disease (Fexuprazan) and Type 2 diabetes (Enavogliflozin) in consecutive years. The company is also developing a first-in-class oral anti-fibrotic agent for idiopathic pulmonary fibrosis (Bersiporocin), which has received both orphan drug designation and Fast Track status from the US FDA. Daewoong Therapeutics Inc., is a subsidiary of Daewoong Group located in South Korea. The company is focused on developing novel drug delivery systems including the dissolving microneedle platform, CLOPAM®. CLOPAM® is currently being applied to various fields including obesity/metabolic diseases and others with aims to improve patient convenience and medication adherence.
